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Abstract
Background:  Treating anemia associated with chemotherapy and many cancers is often
necessary. However, patient satisfaction with anemia treatment is limited by the lack of validated
instruments. We developed and validated a new treatment-specific patient satisfaction instrument:
the Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-An). Treatment burden and
overall satisfaction scales were designed for ease of use in clinical practice.
Methods: 312 cancer patients (141 breast, 69 gynecological, and 102 non-small cell lung) were
targeted to complete the PSQ-An at 4 week intervals. Data from weeks 5 and 9 were analyzed.
Patients also completed the MOS SF-36 Global Health assessment and questions concerning
resources devoted to anemia treatment. Item reduction used endorsement rates, floor/ceiling
effects, and item-item correlations. Factor analysis identified meaningful subscales. Test-retest
reliability was assessed. Construct validity was tested, using Pearson's correlations, by comparing
subscale scores to Global Health, hemoglobin levels, and resources devoted to anemia treatment.
Results: The overall response rate was 92.9% (264/284) at week 5. Most (84.2%) of the patients
were female, and the mean (SD) age was 60.2 (± 11.8) years. Two distinct subscales were identified
measuring treatment burden (7 items) and overall satisfaction (2 items). Test-retest reliability was
examined (ICC: 0.45–0.67); both were internally consistent (alpha = 0.83). Both subscales exhibited
convergent and divergent validity with independent measures of health. ANOVA results indicated
that the PSQ-An Satisfaction subscale discriminated between 5 levels of MOS SF-36 Global Health
(P = 0.006).
Conclusion: The PSQ-An is a validated, treatment-specific instrument for measuring satisfaction
with anemia treatment for cancer patients. PSQ-An subscales reflect the burden of injection anemia
treatment on cancer patients and their assessment of the overall treatment value.
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Background
Anemia and subsequent fatigue have long been recog-
nized as common side effects of cancer itself and its treat-
ments [1,2]. Depending on the type and stage of cancer
and the definition of anemia, the prevalence of anemia
among cancer patients may be quite high. Rates of anemia
(hemoglobin [Hb] <12.0 g/dL) have been reported to be
41% to 82% among breast cancer patients [3-5], 48% to
84% in lung cancer patients [3,5], and 26% to 85%
among patients with ovarian or cervical cancer [3,5,6].
Furthermore, the presence of anemia is associated with
decreased health-related quality of life (HRQL). Holzner
[7] found a correlation between HRQL and Hb levels in
mildly anemic patients (Hb >10.0 g/dL). Lind et al [8]
reported a significant correlation between Hb levels and
HRQL scores. At the same time, anemia treatments them-
selves have shown mostly positive results in improving
HRQL in patients responding to treatment [9-14].
Satisfaction with treatment is an important, but poorly
studied, aspect of the quality of treatment in supportive
oncology care. However, despite the high prevalence of
anemia and the growing recognition of treating anemia in
cancer patients, there is no assessment tool for evaluating
cancer patients' satisfaction with anemia treatment.
Defined as a patient-reported assessment of receiving
treatment and the outcomes of treatment [15], treatment
satisfaction is important for a number of reasons. Fore-
most is the link with compliance and adherence to treat-
ments [16-18]. Treatment satisfaction may also be an
important measure for physicians and patients when
choosing appropriate treatments, especially when the
options have similar efficacy. Finally, competition among
providers in today's healthcare marketplace has elevated
the importance of patients' assessments of the quality of
their healthcare [19]. Patient satisfaction measures have
been studied for general medical and pharmacy services as
well as for treatment of specific conditions [20-25].
We developed and validated the Patient Satisfaction
Questionnaire for Anemia Treatment (PSQ-An), a disease-
and treatment-specific instrument for measuring satisfac-
tion with anemia treatment for cancer patients. The
instrument addresses the gap in treatment evaluation
tools for oncology care. The PSQ-An was designed to
include domains that capture patients' satisfaction with
the treatment itself and to include domains pertaining
directly to anemia treatment: patient's general satisfaction
with treatment, convenience of treatment for patient and
family/friends, patients' pain and discomfort, and finan-
cial aspects of treatment for the patient. This study reports
on the development and validity testing of the scale part
of the PSQ-An instrument. Since most enrolled patients
were women due to inclusion criteria, this effort should
be viewed as an initial validation of the tool; as with most
PRO measures, further validation in other patient popula-
tions is warranted.
Methods
Patients
The study protocols were approved by the Institutional
Review Boards of participating medical centers, and all
patients provided written informed consent before any
study-related procedures were performed. Patients in the
3 trials were required to have a diagnosis of breast cancer,
non-small cell lung cancer (NSCLC; stage IIIb or IV), or
gynecologic carcinoma of the ovary, cervix, or uterus.
Additional inclusion criteria were the following: ≥ 18
years old, anemic (Hb <11 g/dL at screening), expecting to
receive ≥ 8 additional weeks of chemotherapy, a Karnof-
sky performance scale score ≥ 50%; adequate renal func-
tion (serum creatinine concentration ≤2.0 mg/dL),
adequate liver function (aspartate aminotransferase or
alanine aminotransferase ≤ 2 times the upper limit of the
normal range or serum bilirubin ≤ 1.5 times the upper
limit of the normal range), and able to complete ques-
tionnaires. Patients were excluded from the trials if they
had received a red blood cell transfusion within 4 weeks
of screening, or erythropoietic therapy within 2 weeks of
randomization; had inadequate iron stores (transferrin
saturation < 15% and ferritin < 10 ng/L); known positive
antibody response to any erythropoietic agent; known
history of pure red cell aplasia, of anemia due to hemato-
logic disorders other than chemotherapy-induced ane-
mia, or of uncontrolled hypertension.
Initial item development
The components of the PSQ-An were drawn from other
patient satisfaction instruments [26] for other injection
treatments (eg, insulin injections, growth factor injec-
tions) [27,28]. Questions from these components were
selected as candidate questions for the PSQ-An if they
could be modified to capture 1 of the 4 preselected
domains of patient satisfaction for anemia treatment
(general patient satisfaction, convenience of treatment for
the patient and their family and friends, patients' pain and
discomfort, and financial burden for the patient). These
domains were first identified from the literature review
and then selected by the study team based on their rele-
vance to anemia treatment. Redundant questions thought
to be capturing the same information as other questions
were removed to decrease the size of the final question-
naire. The result was a provisional 21-item instrument
comprising 2 parts: a descriptive part (11 items), which
included questions about resources devoted to treatment,
and a scale part (10 items), which included questions
about treatment burden and overall satisfaction. The
questionnaire is presented in Appendix (see Additional
file 1).Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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Study design
The study sample consisted of 312 adult, English-speak-
ing patients participating in 3 randomized, multicenter
trials. This sample size ensures a precision of <5% in the
standard errors assuming treatment compliance rates of
better than 70%. For logistical and administrative reasons,
3 identical but separate protocols were used, 1 for each
tumor type (breast cancer, non-small cell lung cancer,
gynecologic carcinoma) with a preplanned analysis of all
individual data across studies prespecified in each proto-
col. Patients with breast cancer (n = 141), gynecological
malignancies (n = 69), or non-small cell lung cancer (n =
102) were enrolled in the study and were randomized to
treatment with darbepoetin alfa or epoetin alfa for anemia
due to chemotherapy. The inclusion of patients with 3 dif-
ferent tumor types reduces the likelihood that treatment
satisfaction responses are unique to a single population of
cancer patients. Following a 1-week screening period,
complete blood counts (including Hb) were measured
every 2 weeks prior to dosing. In addition, the 4-week
recall patient satisfaction questionnaire was administered
at weeks 5, 9, 13, and 17.
Other study measures
Karnofsky Performance Status ratings (0% – Dead to
100% – Normal, no complaints, no evidence of disease)
were collected in the trial and converted to Eastern Coop-
erative Oncology Group (ECOG) Performance Status Rat-
ings to reduce the number of categories with very small
numbers of patients used in this analysis. The ECOG Per-
formance Status Rating measures how cancer affects the
daily living abilities of the patient [29]. The scale ranges
from 0 (fully active, no restrictions) to 5 (dead), where
lower scores represent better mobility.
The 1-item self-report Global Health question from the
MOS SF-36 was included ("In general, would you say your
health is...?") with a 5-point Likert Scale, where a higher
score represented better health.
Development of the PSQ-An
The items in the scale part of the instrument originally
had response values of 0 to 4 (not at all/mildly/some-
what/moderately/extremely). Values of the 7 negatively
stated questions (items 1, 3, 4, 5, 6, 7, and 8) were reverse
scored, so that higher values indicate more positive satis-
faction. Items were considered for deletion if they met any
of the following 3 criteria: 1) missing responses greater
than 10% (endorsement rate); 2) more than 50% of par-
ticipants reporting either the highest or lowest score avail-
able (floor/ceiling effect); or 3) significant item-item
correlations ≥ 0.70 [30]. All analyses were completed for
data collected at week 5 (test-retest analyses also included
data collected at week 9 to maximize available sample
size).
Principal component analysis was used to identify mean-
ingful and interpretable factors. The number of factors to
retain was based on eigenvalues ≥ 1, with factor loadings
serving as an indicator of the degree to which each item
was associated with each factor. Items were retained in a
given factor if they had a factor loading ≥ 0.40. Multi-trait
scaling was carried out to evaluate item convergence
within scales and item discrimination across scales. A pri-
ori instrument reliability criteria included: 1) item correla-
tion ≥ 0.40 with the total questionnaire (ie, item-internal
consistency) [30,31], and 2) Cronbach's alpha coeffi-
cients = 0.70 (internal consistency) [32].
Test-retest reliability or reproducibility was assessed using
the intraclass correlation coefficients (ICC) [33].
Responses to the MOS SF-36 Global Health question were
used to identify participants with stable health status (ie,
whose responses did not change across weeks 5 through
9). ICCs were computed based on this subsample, for the
5 subscale scores at both time points. A predetermined
threshold for test-retest reliability was defined as an ICC
of 0.70 or greater [32,34].
Convergent and divergent validity were examined by esti-
mating Pearson's correlation coefficient and Spearman's
rank-order correlation coefficient, between subscales of
the PSQ-An and the MOS SF-36 Global Health, Hb level,
and measures of time devoted to treatment hypothesized
to assess either similar or different constructs [35-37]. We
hypothesized that the scores for the subscales of the PSQ-
An measuring aspects of treatment burden would corre-
late more strongly with the questions relating to time
devoted to treatment. Further, the satisfaction subscale of
the PSQ-An was expected to have a larger correlation coef-
ficient with the MOS SF-36 Global Health score and Hb
level than with resources devoted to treatment. The above
correlation coefficients with the MOS SF-36 Global
Health score and Hb levels were hypothesized to be posi-
tive and those with measures of time required for treat-
ment were expected to be negative.
Discriminant validity was assessed by relating PSQ-An
subscale factor scores to 3 variables measuring different
aspects of patient health: MOS SF-36 Global Health score,
Hb level, and ECOG scores. Mean scores on the subscales
of the PSQ-An were compared across response categories
of the 3 known measures using analyses of variance
(ANOVA) [38]. Responsiveness was evaluated by 1) week
5 to 9 effect sizes and 2) ANOVA on week 5 to 9 changes
in each PSQ-An subscale and changes in MOS SF-36 Glo-
bal Health responses. Weeks 5 and 9 were chosen as the
best balance between adequate sample size due to patient
drop-out in the study and time required for anemia treat-
ments to be effective.Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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Statistical analyses were performed using SAS version 8.2
for UNIX (SAS Institute, Cary, NC).
Results
Sample characteristics
The flow of patients initially enrolled in the study is
depicted in Figure 1. Note that by week 9, only 80% of the
patients remained in the study. Of the 284 patients
enrolled at week 5, 264 (92.9%) participants completed
the questionnaires at week 5. Table 1 summarizes the
demographic and clinical characteristics of the study
group classified by anemia treatment. Due to inclusion of
breast and gynecological cancers, the sample was prima-
rily female (84.2%, Table 1). Mean ages were 58.7 (11.5)
and 61.7 (12.1) respectively in the darbepoetin alfa and
epoetin alfa treatment groups. A total of 84.2% percent of
the participants were non-Hispanic Whites. Nearly half of
all participants (48.4%) had Stage IV cancer.
Item reduction
Response rates on all PSQ-An question items were greater
than 90% (Table 2). Mean, standard deviation, and pro-
portion reporting extreme values for each item are also
reported in Table 2. As can be seen, 3 items exhibited ceil-
ing effects with over 50% of responses at the highest score
(difficulty receiving injection, financial burden, and like-
lihood of recommendation). Because the highest
response marker for each item represented highest satis-
faction and effectively captured potential dissatisfaction,
we retained these items for further factor development.
Two item-item pairs exhibited correlation coefficients
near or greater than 0.70 (Table 3). Interference with daily
activities due to treatment-related travel and overall satis-
faction were correlated at r = 0.68 (P < 0.001). Overall sat-
isfaction and likelihood of recommending treatment had
r = 0.77 (P < 0.001). All 3 items were retained since the
Patient Flow Diagram Figure 1
Patient Flow Diagram. Initial sample sizes and proportion remaining at week 9 shown.
Randomized
(n=318)
Breast
(n=142)
Lung
(n=104)
Gynecologic
(n=72)
Not treated
(n=1)
Treated and 
included in 
PSQ-An
(n=141, 
83%@ wk9)
Not treated
(n=2)
Treated and 
included in 
PSQ-An
(n=102, 
74%@ wk9)
Not treated
(n=3)
Treated and 
included in 
PSQ-An
(n=69, 
83%@ wk9)Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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correlations were at or just above the predetermined
threshold for consideration and we felt each item meas-
ured distinct aspects of treatment burden and satisfaction.
Subscale development
Two subscales were identified by factor analysis (Table 4).
The first factor was composed of 7 questions that measure
burden of treatment, inconvenience, and physical pain.
The second factor contained 2 items capturing overall sat-
isfaction. Internal consistency for each subscale is 0.83 (P
< 0.001). Test-retest reliability was moderate between
weeks 5 and 9 in patients with stable MOS SF-36 Global
Health scores (128/284 participants). The item ("relating
to difficulty in receiving every injection") did not load
Table 2: Response rate, percentage of patients choosing the lowest response marker, and percentage of patients choosing the highest 
response marker
Question Item Mean (SD) Response rate (%) % with lowest marker % with highest marker
Demands of treatment 3.14 (1.09) 92 3.2 46.5
Schedule flexibility 2.97 (1.42) 92 11.3 49.7
Difficulty in receiving every injection 3.68 (0.79) 93 1.8 75.7
Treatment-related travel interference w/daily activity 3.12 (0.98) 93 1.4 40.9
Overall inconvenience 3.27 (0.97) 93 1.8 48.6
Inconvenience to family/caregivers 3.23 (1.05) 93 2.5 49.7
Overall physical discomfort from injections 3.00 (1.02) 93 2.1 36.3
Financial burden from out-of-pocket costs 3.62 (0.75) 93 0.4 66.9
Satisfaction with treatment 3.20 (1.08) 93 2.8 46.8
Likelihood of recommending treatment 3.21 (1.10) 93 4.2 51.1
Table 1: Baseline Sample Characteristics
Darbepoetin alfa (n = 157) Epoetin alfa (n = 155)
Sex, n (%)
Male 23 (15) 26 (17)
Female 134 (85) 129 (83)
Race, n (%)
White 132 (84) 131 (85)
Black 16 (10) 11 (7)
Hispanic 3 (2) 6 (4)
Asian 6 (4) 5 (3)
Other 0 (0) 2 (2)
Age (years)
Mean (SD) 58.7 (11.5) 61.7 (12.1)
Tumor type, n (%)
Breast 72 (46) 69 (45)
Non Small Cell Lung (stage IIIb/IV) 51 (32) 51 (33)
Gynecologic 34 (22) 35 (23)
Stage of Disease
I/II 41 (26) 28 (18)
III 29 (18) 27 (17)
IIIb 15 (10) 14 (9)
IV 70 (45) 81 (52)
Unknown 2 (1) 5 (3)
Karnofsky Performance Status, n (%)
100 18 (11) 18 (12)
80, 90 104 (66) 103 (67)
60, 70 35 (22) 33 (22)
≤50 0 (0) 1 (1)
Hb (g/dL)
Mean (SD) 10.4 (0.8) 10.4 (0.8)
Median 10.6 10.6
Hb, n (%)
<10 g/dL 38 (24) 38 (25)
≥10 g/dL 119 (76) 117 (75)Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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strongly on either subscale and was excluded from further
analyses.
Construct validity
The Inconvenience subscale correlated negatively with
descriptive questions on resources devoted to treatment
(Table 5, r = -0.19 to -0.61). The Satisfaction subscale cor-
related positively with MOS SF-36 Global Health (r = 0.13
to 0.25) and negatively with resources devoted to treat-
ment (r = -0.22 to -0.28). These relationships were largely
as hypothesized. However, neither subscale correlated sig-
nificantly with Hb levels at either week 5 or 9. These
results are consistent using both Pearson's correlation
coefficients and Spearman's rank-based correlation coeffi-
cients.
Test of known-groups discriminant validity
The 2 PSQ-An subscales correlated moderately with MOS
SF-36 Global Health score, Hb level, and ECOG scores
(Table 6). ANOVA showed that only the Satisfaction sub-
scale had a significant (P = 0.006) relationship with Glo-
bal Health.
Effect size and responsiveness
The effect size between week 5 and week 9 for the Satisfac-
tion subscale was 0.44 (Table 7). This is a moderately
large detectable change over this period. In contrast, the
Table 4: Factor Scores and Subscales, Internal Consistency, and Inter-Rater Reliability
Subscale
Item Inconvenience (n = 266) Satisfaction (n = 265)
Demands of treatment 0.595 0.103
Schedule flexibility 0.600 0.094
Difficulty in receiving every injection 0.057 0.241
Treatment-related travel interference w/daily activity 0.710 -0.007
Overall inconvenience 0.878 -0.110
Inconvenience to family/caregivers 0.714 -0.038
Overall physical discomfort from injections 0.451 0.187
Financial burden from out-of-pocket costs 0.507 0.038
Satisfaction with treatment -0.037 0.813
Likelihood of recommending treatment 0.084 0.761
Cronbach's Alpha (week 5) 0.83 (P < 0.001) 0.83 (P < 0.001)
ICC (weeks 5–9), patients with stable MOS Global Health 0.67 (P = 0.210) 0.45 (P = 0.020)
Note: Components of each subscale are denoted in bold.
Table 3: Item-Item Correlation Coefficients (Spearman's rho)
I t e m 12345678 9 1 0
1. Demands of treatment 1
2. Schedule flexibility 0.192* 1
3. Difficulty in receiving every injection 0.399*
*
0.217** 1
4. Treatment-related travel interference w/daily 
activity
0.468*
*
0.130 0.367** 1
5. Overall inconvenience 0.524*
*
0.119 0.503** 0.682** 1
6. Inconvenience to family/caregivers 0.377*
*
0.119 0.257** 0.495** 0.557** 1
7. Overall physical discomfort from injections 0.368*
*
0.123 0.393** 0.313** 0.347** 0.265** 1
8. Financial burden from out-of-pocket costs 0.404*
*
0.245** 0.341** 0.375** 0.369** 0.412** 0.240** 1
9. Satisfaction with treatment 0.277*
*
0.245** 0.250** 0.189* 0.130 0.151 0.322** 0.228** 1
10. Likelihood of recommending treatment 0.316*
*
0.168* 0.261** 0.252** 0.230** 0.213** 0.271** 0.239** 0.765** 1
*P < 0.010
**P < 0.001Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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effect size for the Inconvenience subscale was a moderate
0.13. Changes over this period in the Satisfaction subscale
also correlated with changes in MOS SF-36 Global Health
over this period (Table 8). The trends in changes in the
Inconvenience subscale scores and in changes in MOS SF-
36 Global Health were not statistically significant.
Discussion
The results from this study support the validity and relia-
bility of the scale part of the Patient Satisfaction Question-
naire for Anemia Treatment (PSQ-An) for measuring
satisfaction with anemia injection treatment for cancer
patients. Item-item correlations were moderate and sug-
gested that the individual question items measured dis-
Table 6: Results of ANOVA for known group discriminant validity
PSQ-An Subscale
Inconvenience Satisfaction
Item Response Category nM e a n  ( S D ) P value n Mean (SD) P value
Self-Reported 
General Health
Poor 22 3.06 (0.95) 0.13 22 2.95 (1.14) 0.006
Fair 108 3.24 (0.64) 107 2.99 (1.03)
Good 93 3.37 (0.58) 93 3.35 (0.92)
Very Good 27 3.47 (0.71) 27 3.53 (0.81)
Excellent 12 3.12 (0.99) 12 3.67 (0.58)
Hb level (CTC) >12.0 g/dL (female); >14.0 g/dL (male) 27 3.26 (0.68) 0.17 26 3.25 (0.95) 0.83
10.0 – 12.0 g/dL (female); 10.0 – 14.0 g/dL (male) 104 3.23 (0.71) 104 3.04 (1.07)
8.0 – 10.0 g/dL 20 3.57 (0.30) 20 3.10 (1.00)
<8.0 g/dL 2 3.64 (0.51) 2 3.00 (1.41)
ECOG Score* 0. Fully active, able to carry on all pre-disease performance without 
restriction
151 3.26 (0.72) 0.58 151 3.20 (1.00) 0.18
1. Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, eg, light house work, 
office work
101 3.34 (0.63) 100 3.09 (1.03)
2. Ambulatory and capable of all self care but unable to carry out any 
work activities. Up and about more than 50% of waking hours
14 3.17 (0.70) 14 3.61 (0.68)
* The conversion between Karnofsky and ECOG performance status ratings may be found at http://www.canceralternatives.mednet.ucla.edu/
under.html#Anchor-ECOG-47833
Table 5: Correlation Coefficients between Each PSQ-An Subscale and other Measure Scores
Subscale
Inconvenience (n = 266) Satisfaction (n = 265)
Week 5 Week 9 Week 5 Week 9
Item Pearson Spearman Pearson Spearman Pearson Spearm
an
Pearso
n
Spearm
an
General Health 0.096 0.135 0.123 0.141 0.224* 0.248** 0.176* 0.133*
Hb level -0.043 -0.065 -0.112 -0.079 0.033 0.040 0.072 0.038
Resources devoted to injections for anemia 
treatment during the past 4 weeks:
Number of office visits -0.047 -0.028 -0.164 -0.087 -0.062 -0.049 -0.018 0.012
Time spent traveling for office visits for each injection -0.153 -0.188* -0.203 -0.223* -0.078- 0 . 1 5 00 . 0 0 1- 0 . 0 4 8
Time spent at the office to review your injection -0.195* -0.135 -0.314** -0.245 -0.260** -0.228* -0.149 -0.231*
Number of times family/friends/caregiver 
inconvenienced
-0.527** -0.514** -0.361** -0.607** -0.191 -0.249** -0.123 -0.137
Out-of-pocket expenses related to injections -0.264** -0.276** -0.148 -0.380** -0.000 -0.049 0.035 -0.012
Number of times schedule was rearranged for office 
visits
-0.186 -0.476** -0.545** -0.556** 0.004 -0.066 -0.074 -0.113
Hours of work missed due to injections -0.181 -0.351** -0.219 -0.316 0.004 -0.076 -0.095 -0.072
Time activities of daily living reduced due to injections -0.324** -0.522** -0.394** -0.535** -0.158 -0.280** -0.073 -0.176
About how many hours did caregivers miss from 
work
-0.367** -0.442** -0.240 -0.431** -0.049 -0.103 0.039 -0.082
*P < 0.010, **P < 0.001Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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tinct constructs. There were moderate ceiling effects on
several component question items, perhaps reflecting dif-
ficulty in measuring high levels of satisfaction. This effect
lowered variance in the PSQ-An subscales, which in turn
may have led to the moderate results seen in some of the
validity tests. For example, the moderate trends noted in
convergent, divergent, and known-group discriminant
validity may have been due, in part, to limited variation in
the subscales. With 40% or more patients reporting high
satisfaction on most question items, the potential strength
of trends with independent measure of health status are in
turn reduced.
Items loaded distinctly onto the 2 subscales and internal
consistency of both the Inconvenience and Satisfaction
subscales were high. Despite including only patients with
stable MOS SF-36 Global Health for the test-retest assess-
ment, the subscale scores of the PSQ-An had moderate
reproducibility over a 4-week test-retest timeframe (ICC =
0.45 for Satisfaction and 0.67 for Inconvenience). These
results were not unexpected given the potential improve-
ment in anemia over 4 weeks of treatment. This suggests
that overall satisfaction with treatment may change sub-
stantially over the 4-week study period even when con-
trolling for overall health status. Indeed, the effect size for
the Satisfaction subscale shows that patients' value assess-
ments of the treatment underwent large changes over the
study period.
This study has several limitations. First, this study
included primarily female patients due to the inclusion
criteria, so further evaluation of the PSQ-An is warranted
prior to use in other patient populations. Second, the ini-
tial item pool was drawn from the literature, not devel-
oped from patient focus groups. Nor were these items
cognitively tested in patient focus groups. Input from
patients may have revealed additional concepts of satis-
faction not incorporated into current literature on which
our item pool was based. Cognitive testing or debriefing
may also have improved the wording/content of the ques-
tionnaire; for example, it may have identified better
response scales with less potential for ceiling effects.
Third, we did not stratify our validation and analysis by
disease stage. It is possible that patients with stage IV can-
cers (48% of our sample) respond quite differently to
treatment satisfaction questions than do patients with
lesser progression. Again, extrapolations to other patient
populations should be made cautiously. Finally, while it
is unlikely that the observed ceiling effects are due to
response bias, in its present form the PSQ-An may not
fully capture the range of satisfaction cancer patients can
express about anemia treatment. Consideration could be
given to additional response categories to encompass a
broader spectrum of satisfaction responses.
The Patient Satisfaction Questionnaire for Anemia Treat-
ment (PSQ-An) is a validated, treatment-specific instru-
ment for measuring satisfaction with anemia treatment
for cancer patients. The 2 subscales of the PSQ-An reflect
Table 8: ANOVA for Week 5-Week 9 Differences in Subscales by MOS Global Health
Change in Subscale
Inconvenience Satisfaction
Change in MOS Global 
Health
n mean (SD) n mean (SD)
1 (decrease) 36 -0.011 (0.56) 36 -0.042 (0.80)
2 (no change) 128 -0.038 (0.51) 127 0.063 (0.90)
3 (improvement) 44 -0.078 (0.66) 43 0.407 (1.08)
F 0.16 2.87
Pr > F 0.850 0.059
Table 7: Subscale Effect Sizes at Week 5 and Week 9 for Patients with Improved MOS Global Health
PSA-An Subscale
Inconvenience Satisfaction
Time Period n mean (SD) n mean (SD)
Week 5 266 3.26 (0.63) 265 2.95 (1.11)
Week 9 223 3.18 (0.64) 222 3.35 (0.62)
Effect Size week 5–9 0.13 0.44Health and Quality of Life Outcomes 2006, 4:28 http://www.hqlo.com/content/4/1/28
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the burden of injection anemia treatment on cancer
patients and their assessment of the overall value of that
treatment. This instrument has potential to aid clinicians
in their understanding of the various aspects of patient
satisfaction with anemia treatment and allow clinicians to
optimize patient care.
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